Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol

BACKGROUND: Between 30 and 50% of patients with major depressive disorder (MDD) do not respond sufficiently to antidepressant regimens. The conventional pharmacological treatments predominantly target serotonergic brain signaling but better tools to predict treatment response and identify relevant s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Psychiatry
Main Authors: Köhler-Forsberg, Kristin, Jorgensen, Anders, Dam, Vibeke H., Stenbæk, Dea Siggaard, Fisher, Patrick M., Ip, Cheng-Teng, Ganz, Melanie, Poulsen, Henrik Enghusen, Giraldi, Annamaria, Ozenne, Brice, Jørgensen, Martin Balslev, Knudsen, Gitte Moos, Frokjaer, Vibe Gedsoe
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Psychiatry
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7391965/
https://ncbi.nlm.nih.gov/pubmed/32792991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpsyt.2020.00641
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados